Latest news
Eli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Months - StocktwitsStocktwits · Sat, 08 Aug 2026 08:49:38 GMTCVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal - Pharmacy TimesPharmacy Times · Fri, 07 Aug 2026 16:09:33 GMTEli Lilly stock surges 5% after raising 2026 revenue guidance to $85–$87B - eciks.orgeciks.org · Thu, 06 Aug 2026 10:58:49 GMTLilly Expands Retatrutide Access Amid Doctor Pushback - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Wed, 05 Aug 2026 20:37:18 GMTWhy Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY) - BenzingaBenzinga · Wed, 05 Aug 2026 16:06:02 GMTCVS Health expands GLP-1 offerings with Lilly (LLY:NYSE) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 12:08:55 GMTRetatrutide Expanded Access Draws Mixed Clinician Views - MedscapeMedscape · Wed, 05 Aug 2026 10:21:16 GMTNovo Nordisk sues Eli Lilly over GLP-1 advertising, expanding scrutiny of drug marketing - Telehealth.orgTelehealth.org · Wed, 05 Aug 2026 09:45:00 GMT